Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-

Study Overview
=================
Brief Summary
-----------------
Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is responsible for a significant increase in mortality (up to 31% of increase in thrombosis risk in ET). Cellular inflation and blood hyperviscosity, resulting from these diseases, fail to account for these thromboses, as more than 50% of thrombotic complications happen under adapted antineoplastic drug treatment. These last years, cellular microparticles (MPs) have been shown to play a major role in thrombogenesis. MPs are generated by apoptosis or the activation of malignant cells, platelets, endothelial cells or monocytes. They are fragments of plasma membrane, smaller than 1 µm, rich in phosphatidylserine, which can express the tissue factor and serve as support for the coagulation factors. Increase in the plasma concentration of procoagulant platelet microparticles has been demonstrated in other thrombotic diseases (acute coronary syndrome, disseminated intravascular coagulation DIC, etc.). The working hypothesis is that platelet microparticles are involved in the hypercoagulability of MPNs patients.

Official Title
-----------------
Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms

Conditions
-----------------
Myeloproliferative Neoplasm

Intervention / Treatment
-----------------
* Other: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for MNPs patients: Age > 18 Establish MNPs Phi- diagnosis (ET, PV, MFP) Consent to participate Inclusion Criteria for healthy volunteers: Healthy volunteers matched in age, sex with the MNPs patients, with a normal complete blood and platelet count No personal thromboembolic history No known thromboembolic risk factor : thrombophilia, cancers, and other disease associated with a thrombotic risk (Atrial fibrillation, etc.) Not pregnant Non smoker For women, no hormonal contraceptives Exclusion Criteria for MNPs patients: Pregnancy Patient unable to give consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Primary Myelofibrosis (PMF)<br>Blood sampling during routine visit | Other: Blood sampling<br>* Blood sampling every 6 month following the routine calendar of visit<br>|
| Essential thrombocytosis (ET)<br>Blood sampling during routine visit | Other: Blood sampling<br>* Blood sampling every 6 month following the routine calendar of visit<br>|
| Polycythemia vera (PV)<br>Blood sampling during routine visit | Other: Blood sampling<br>* Blood sampling every 6 month following the routine calendar of visit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the average number of microparticles detected by flow cytometry in all subgroup |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
myeloproliferative neoplasms, Circulating Procoagulants Microparticles